Are there any association between COVID-19 severity and immunosuppressive therapy?
作者信息
Hormati Ahmad, Ghadir Mohammad Reza, Zamani Farhad, Khodadadi Javad, Khodadust Fatemeh, Afifian Mahboubeh, Aminnejad Reza, Ahmadpour Sajjad
机构信息
Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran; Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran.
出版信息
Immunol Lett. 2020 Aug;224:12-13. doi: 10.1016/j.imlet.2020.05.002. Epub 2020 May 28.
Abstract
摘要
相似文献
1
Are there any association between COVID-19 severity and immunosuppressive therapy?
Immunol Lett. 2020 Aug;224:12-13. doi: 10.1016/j.imlet.2020.05.002. Epub 2020 May 28.
2
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.
Mult Scler Relat Disord. 2020 Jun;41:102135. doi: 10.1016/j.msard.2020.102135. Epub 2020 Apr 18.
3
The complement inhibitors in COVID-19: future expectations.
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6480-6481. doi: 10.26355/eurrev_202006_21628.
4
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
5
Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab.
Diagn Interv Imaging. 2020 May;101(5):323-324. doi: 10.1016/j.diii.2020.03.010. Epub 2020 Mar 31.
6
Tocilizumab for COVID-19: a real 'miracle drug'?
Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.
7
COVID-19 in an elderly patient treated with secukinumab.
Dermatol Ther. 2020 Jul;33(4):e13580. doi: 10.1111/dth.13580. Epub 2020 May 27.
8
Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.
9
Treatment considerations for patients with pemphigus during the COVID-19 pandemic.
J Am Acad Dermatol. 2020 Jun;82(6):e235-e236. doi: 10.1016/j.jaad.2020.04.005. Epub 2020 Apr 10.
10
Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.
J Clin Virol. 2020 Jun;127:104380. doi: 10.1016/j.jcv.2020.104380. Epub 2020 Apr 21.
引用本文的文献
1
Diagnosis of Good Syndrome following Recurrent Coronavirus Disease-2019 Infections.
Case Rep Oncol. 2025 Jan 14;18(1):107-112. doi: 10.1159/000542928. eCollection 2025 Jan-Dec.
2
A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19.
medRxiv. 2025 Jan 14:2025.01.10.25320348. doi: 10.1101/2025.01.10.25320348.
3
Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide.
Middle East J Dig Dis. 2022 Jan;14(1):5-23. doi: 10.34172/mejdd.2022.251. Epub 2022 Jan 30.
4
Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review.
Middle East J Dig Dis. 2022 Apr;14(2):155-166. doi: 10.34172/mejdd.2022.269. Epub 2022 Apr 30.
5
Gastrointestinal and Liver Manifestations in COVID-19 Population.
Middle East J Dig Dis. 2021 Oct;13(4):281-286. doi: 10.34172/mejdd.2021.236. Epub 2021 Sep 3.
6
Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.
Sci Rep. 2022 Dec 9;12(1):21333. doi: 10.1038/s41598-022-25429-2.
7
Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases.
Children (Basel). 2021 Aug 30;8(9):753. doi: 10.3390/children8090753.
8
Gastrointestinal manifestations with COVID-19 virus infection: A Moroccan prospective study.
Arab J Gastroenterol. 2021 Dec;22(4):305-309. doi: 10.1016/j.ajg.2021.07.004. Epub 2021 Jul 30.
9
IL10RB as a key regulator of COVID-19 host susceptibility and severity.
medRxiv. 2021 Jun 2:2021.05.31.21254851. doi: 10.1101/2021.05.31.21254851.
10
Risk of Severe Covid-19 in Patients with Celiac Disease: A Population-Based Cohort Study.
Clin Epidemiol. 2021 Feb 18;13:121-130. doi: 10.2147/CLEP.S294391. eCollection 2021.
本文引用的文献
1
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat.
J Infect Public Health. 2020 Apr;13(4):644-646. doi: 10.1016/j.jiph.2020.02.033. Epub 2020 Mar 19.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
5
Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.
J Med Virol. 2020 Apr;92(4):401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12.
Zotero 插件